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Abstract 
It is unknown whether adipokines derived from  adipose tissues modulate endoplasmic 
reticulum (ER) stress induced in obesity. Here we show that visceral adipose tissue-
derived serine protease inhibitor (vaspin) binds to cell-surface 78-kDa glucose-regulated 
protein (GRP78), which is recruited from ER to plasma membrane under ER stress. 
Vaspin transgenic mice were protected from diet-induced obesity, glucose intolerance, 
and hepatic steatosis, while vaspin-deficient mice developed glucose intolerance 
associated with upregulation of ER stress markers. With tandem affinity tag purification 
using HepG2 cells, we identified GRP78 as an interacting molecule. The complex 
formation of vaspin, GRP78, and murine tumor cell DnaJ-like -protein 1 (MTJ-1) (DnaJ 
homolog, subfamily C, member 1) on plasma membrane was confirmed by cell-surface 
labelling with biotin and immunoprecipitation in liver tissues and H-4-II-E-C3 cells. 
The addition of recombinant human vaspin in the cultured H-4-II-E-C3 cells also 
increased the phosphorylation of Akt and AMP-activated protein kinase (AMPK) in a 
dose-dependent manner, and anti-GRP78 antibodies completely abrogated the vaspin-
induced upregulation of pAkt and pAMPK. Vaspin is a novel ligand for cell-surface 
GRP78/MTJ-1 complex, and its subsequent signals exert beneficial effects on ER 
stress-induced metabolic dysfunctions.  
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Introduction 
Obesity is associated with low-grade and chronic inflammation, which is a critical link 
between obesity and related metabolic dysfunction, such as insulin resistance and type 2 
diabetes. Upstream of the obesity-induced inflammatory responses, endoplasmic 
reticulum (ER) stress and related signalling networks are emerging as a potential site for 
the interaction of inflammation and metabolic diseases (1). ER stress is induced by the 
accumulation of de novo synthesized unfolded proteins and the unfolded protein 
response (UPR) is activated. The canonical UPR is linked to inflammatory and stress 
signal systems such as nuclear factor-κB (NF-κB)-IκB kinase, Jun NH2-terminal 
kinase-activator protein 1 (AP1) pathways, and oxidative stress responses. Three major 
pathways of UPR, dsRNA-dependent protein kinase-like eukaryotic initiation factor 2α 
kinase (PERK)-mediated attenuation of translation, the activation of inositol requiring 
enzyme 1 (IRE1α) after splicing of mRNA of X-box binding protein 1 (XBP1), and 
activating transcription factor 6 (ATF6) pathway, have all been shown to be linked to 
inflammatory signalling(1). Causality between susceptibility to ER stress and insulin 
resistance has been shown to be supported by genetic manipulation of XBP1(2) and ER 
chaperone proteins such as oxygen-regulated protein 150 (3; 4) and 78-kDa glucose-
regulated protein (GRP78) (5; 6). In previous studies, XBP1 haploinsufficiency in mice 
resulted in insulin resistance(2) and oxygen-regulated protein 150 deficiency resulted in 
impaired glucose tolerance (3; 4). Similarly, overexpression of GRP78 in the liver has 
been shown to result in beneficial metabolic effects in mice (6), and intriguingly, 
GRP78 heterozygosity has been shown to result in a compensatory increase in other ER 
chaperones, which enhanced overall ER capacity and consequently metabolic benefits 
(5). 
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We previously reported the cloning of visceral adipose tissue-derived serine proteinase 
inhibitor (vaspin), belonging to serpin clade A (Serpina12), and suggested that it may be 
a compensatory adipokine to improve insulin sensitivity with anti-inflammatory 
properties demonstrated by recombinant human vaspin protein (rhVaspin) 
administration into DIO mice(7; 8). Since vaspin belongs to serpin, the identification of 
the proteases, which are inhibited by vaspin may lead to the development of novel 
strategies in the treatment of obesity, diabetes, and insulin resistance; however, as of 
now molecular target(s) of vaspin and its mode of action are totally unknown (9). In 
later human studies, elevated serum vaspin concentrations in obesity(10), type 2 
diabetes (11) and polycystic ovary syndrome(12) were reported, and it correlates with 
insulin resistance (homeostasis model assessment of insulin resistance) and C-reactive 
protein levels (13). Here, we show that vaspin exerts its compensatory actions on 
metabolic dysfunction associated with obesity by using genetic manipulation of the 
vaspin gene, i.e. vaspin transgenic (Tg) and knockout mice. Further, we demonstrate 
that vaspin is a ligand for cell-surface-associated GRP78/MTJ-1 complex in the liver 
and provide a new functional insight into and molecular basis for the direct cross-talk 
between an adipokine and ER stress responses in obesity. 
 
Research design and methods 
Generation of vaspin (Serpina12) Tg and knockout mice. β-Globin intron and human 
GH poly A signal were ligated into BamHI-EcoRI and EcoRI-XhoI sites of 
pcDNA3.1Zeo vector (Invitrogen), respectively. Coding region of mouse vaspin 
(Serpina12) cDNA was inserted into EcoRI site by blunt end ligation after filling-in 
reaction. BamHI and XhoI fragment was subjected to blunt end ligation into SmaI site of 
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pBluescript SKII(+) (Stratagene), in which mouse aP2 promoter was inserted into 
EcoRV-PstI site by blunt end ligation(14). The insert was excised with HindIII and 
NotI , and transgene was generated. Microinjected C57BL/6JJcl one-cell stage zygotes 
were oviduct transferred and permitted to develop to term. Three Tg founders were 
obtained, and Southern blot analysis was performed using ApaI fragment of the 
transgene. Genotyping of Tg mice was performed by PCR using primers 5’-
CAAGCTACTGCAGAGGCTGGCCAGCAATAG-3’ and 5’-
GAGAGCTGGCTGTCATAGGCCATGTCGTAC-3’.  
We also constructed a targeting vector for vaspin (Serpina12) using pBI-lx-Neo-DT 
carrying neomycin-resistance gene (Neo) to target exon 2 (Figure S7a)(15). The 5’- and 
3’ homology arms were amplified from mouse genomic DNA using TaKaRa Ex Taq. 
The following primer pairs were used to amplify the homology arms; 5’-
GGATCTGAGGGAAGCTGAGG-3’ and 5’-CCCATCTTAGCCATCATCAGGAG-3’ 
(for the 5’ homology arm) and 5’-GCTAGTCCATCTAGACAATCCG-3’ and 5’-
CCAGCATAGTCGTGAGGATG-3’ (for the 3’ homology arm). Homologous 
recombination of 129P2/OlaHsd embryonic stem cell clones was screened by Southern 
blot using BamHI-digested genomic DNA with 3’-probe. Recombination was further 
confirmed by MunI-digested DNA with 5’-probe and ScaI-ClaI-digested DNA with 
Neo-probe (Figure S7a). Male chimeric mice were mated with C57BL/6JJcl mice to 
generate heterozygous vaspin+/- mice, and they were backcrossed to C57BL/6JJcl mice 
for more than 5 generations. Genotyping of vaspin-/- mice was performed by PCR using 
primers 5’-CCGACTCGAGATAACTTCGT-3’ and   5’-
CTGGAAGGCAAGGACTGACTG-3’, and vaspin+/+ mice were identified by 5’-
GAGGACCTGAGTTCAGACTCC-3’ and CACCGTCCACCAGATTCAGG-3’. 
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Animals. Male mice were housed in cages and maintained on a 12-h light-dark cycle. 
For the animal experiments with mice, standard chow (NMF; Oriental Yeast) and a high 
fat-high sucrose (HFHS) diet (D12331; Research Diet) were used and the mice were 
killed at 25 weeks of age. Oxygen consumption was measured using O2/CO2 
metabolism-measuring system (MK-5000; Muromachi). Ambion In Vivo small 
interference (si)RNA Predesigned siRNA (HPLC In Vivo Ready) was injected into 
vaspin Tg and wild-type (WT) HFHS-diet mice at a dose of 7 mg/kg following the 
protocol supplied with Invivofectamine 2.0 Reagent (Invitrogen). All animal procedures 
were performed in accordance with the Guide for Care and Use of Laboratory Animals 
at the Department of Animal Resources, Advanced Science Research Center, Okayama 
University. Liver triglyceride was measured by Folch method (Skylight Biotech, Tokyo, 
Japan). 
 
Cell culture. H-4-II-E-C3 cells (European Collection of Cell Cultures) were cultured in 
minimum essential medium Eagle containing 2 mmol/L glutamine, 1% nonessential 
amino acids, and 10% FBS. HepG2 cells (American Type Culture Collection) were 
cultured in minimum essential medium Eagle containing 2 mmol/L glutamine, 1 
mmol/L sodium pyruvate, 1% nonessential amino acids and 10% FBS. H-4-II-E-C3 
cells were transfected with 5 multiplicity of infection of MISSION short-hairpin 
(sh)RNA lentivirus transduction particles for GRP78 (GenBank accession number 
NM_022310) and nontarget shRNA control lentivirus transduction particles, and they 
were further treated with various concentrations of rhVaspin. 
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Poly (A+) RNA analysis. For quantitative real-time PCR analysis, cDNA synthesized 
from 2 μg total RNA was analyzed in a sequence detector (model 7900; PE Applied 
Biosystems) with specific primers and SYBR Green PCR Master (PerkinElmer Life 
Sciences). The relative abundance of mRNAs was standardized with 36B4 mRNA as 
the invariant control. The mRNA expression was determined by SYBR green. Gene-
specific primers are indicated in Table S1. 
 
Western blot analysis. Mice were starved overnight, anesthetized with pentobarbital 
and injected with 5 units of regular human insulin into the inferior vena cava, and liver 
was removed 5 min after the injection. Liver tissues were fractionated by discontinuous 
iodixanol gradients following protocol S36 of the manufacturer’s application sheets 
(OptiPrep; Invitrogen). The protein lysates of total and subcellular fractions of liver 
tissues as well as H-4-II-E-C3 were subjected to SDS-PAGE and transferred to 
polyvinylidene fluoride membranes. The membranes were treated with specific 
antibodies (1:200-1,000 dilution): GRP 78 (C-20), PGC-1 (H-300), Na+/K+-ATPase α1 
(N-15), vaspin (I-14) (Santa Cruz), vaspin (Strategic Biosolutions), phospho-Akt 
(Ser473), Akt, phosho-AMP-activated protein kinase (AMPK)α (40H9), SirT1 (C14H4), 
phospho-elF2α (Ser51), GAPDH (14C10) (Cell Signaling); calnexin (ab22595) and  
IRE1α (phosphor-S724) (Abcam); Golgi 58K (58K-9), and DNAJC1 (Sigma) overnight 
at 4°C. Antibody treatment was followed by the treatment with secondary antibodies 
conjugated with horseradish peroxidase, and, finally, visualizaion with ECL Plus (GE 
Healthcare) and a luminescent image analyzer (LAS-3000mini; Fujifilm). 
Immunoprecipitation was performed using Universal Magnetic Co-IP kit (Active Motif). 
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Cell-surface proteins of H-4-II-E-C3 were biotinylated and isolated using Pierce Cell 
Surface Protein Isolation Kit. 
 
Liquid chromatography-tandem mass spectrometry. Recombinant full-length mouse 
vaspin (vaspin-Ad) and vaspin tagged with calmodulin and streptavidin-binding 
peptides (pCTAP-vaspin-Ad) (InterPlay Mammalian TAP system; Stratagene) were 
prepared by Adenovirus Expression Kit (Takara) as described(8). Adenovirus vector 
expressing vaspin tagged with calmodulin and streptavidin-binding peptides (pCTAP-
vaspin-Ad) was introduced to HepG2. Soluble proteins were purified by CBP- and SBP-
binding resin (InterPlay Mammalian TAP System; Stratagene) and subjected to SDS-
PAGE and Coomassie Blue staining. Visible bands were excised and in-gel digested 
with trypsin and analyzed with liquid chromatography-tandem (LC-MS/MS) (16). 
 
Pull-down assay and 125I-vapsin binding analysis. Coding sequences without signal 
peptide of vaspin21-413 and GRP7819-654 were ligated to KpnI-XbaI and SalI-NotI sites of 
pTNT vector (Promega), respectively. Coding sequence without signal peptide of 
vaspin21-413 was ligated to BamHI-XhoI site, GRP78 to SalI – NotI and α1-antitrypsin 
(α1AT)26-417,  and chimeric vaspin21-249/α1AT254-417 and α1AT26-253/vaspin250-413 to 
EcoRI - NotI of pET-42a vector. Pull-down assay was performed with MagneGST Pull-
Down System (Promega). rhVaspin was iodinated with specific activity of 7.8 μCi/μg 
(PerkinElmer) and used for solid-phase assay. Cell-binding assay of cultured H4-II-E-
C3 was performed using 125I-vapsin and subjected to Scatchard analysis. Liver 
membrane fractions were isolated, and the binding activity of  125I-vapsin was also 
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investigated(9).  α2-macrogloburin (α2M) (Abnova), anti-GRP78 (N-20) and anti-
GRP78 (C-20) were used for the pull-down and solid-phase binding assays. 
 
Statistical analysis. Data are expressed as the means ± SEM and analyzed by unpaired 
Student t test in the comparison of two groups and two-way ANOVA in the comparison 
of more than three groups. Oxygen consumption was compared by analysis of 
covariance (ANCOVA) with body weight as a covariant.  P < 0.05 was regarded as 
statistically significant. The data were analyzed with PASW Statistics 18 (SPSS, 
Chicago, IL). 
 
Results 
Vaspin improves insulin sensitivity in vivo. Vaspin Tg C57BL/6JJcl mice under the 
control of aP2 promoter were produced (Figure S1a), and the vaspin levels in serum 
and adipose tissues derived from three independent lines (line 1, line 10 and line 58) 
were comparable, although copy numbers of transgene were different in the three lines 
(Figure S1b-d).  At 25 weeks of age, the body weight gain was ameliorated by ~8% 
(Figure 1a) and fat pad and liver weight were significantly reduced (Figure 1b) in Tg 
mice of line 1 compared with WT mice. Mice fed HFHS chow demonstrated similar 
weight reduction in all three lines (Figure S1e), and the representative data of line 1 are 
shown. Although the pathological features of steatohepatitis such as infiltration of 
inflammatory cells were not observed in either vaspin Tg and WT mice, by Oil red O 
staining, the lipid droplets in the liver were apparently reduced (Figure 1c), and 
triglyceride content was also significantly decreased in HFHS chow Tg mice, 
suggesting that liver may be one of the major target organs of vaspin. In the sera, leptin 
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and insulin levels were significantly reduced at 13 weeks of age in HFHS chow mice, 
but there were no differences at 25 weeks of age (Figure S2a-c). The results suggested 
that vaspin may not completely compensate for insulin resistance associated overall 
with obesity and aging. In addition, vaspin overexression did not alter the serum 
concentration of adiponectin (Figure S2d). Gel filtration HPLC indicated a small 
reduction in the fraction of small dense LDL cholesterol (Figure S2e-g). Glucose 
tolerance and insulin tolerance tests demonstrated improvement of insulin sensitivity in 
Tg mice (Figure 1d, 1e, S3a, S3b). In the liver tissues, real-time PCR demonstrated the 
reduction of gluconeogenic genes G6pc  and Pepck,and lipogenesis genes Acc, Fasn  
and Scd1 (Figure S4a-h). In proinflammatory cytokines, serum interleukin-6 levels 
were significantly reduced in vapsin Tg HFHS chow mice (Figure S4i-k). To survey 
the gene expression profile in adipose tissues, we further evaluated the expression of 
22,626 genes by Mouse Gene 1.0 ST Array (Affymetrix). Among 22,626 genes, 350 
genes and 26 immune response genes revealed significant variation across the samples. 
Hierarchical clustering analysis of these genes revealed that mesenteric gene expression 
profile in vaspin Tg mice fed with high-fat chow was on same branch as in mice fed 
with normal chow, suggesting the expression that the expression pattern of immune 
response genes become close to that of control mice fed with normal chow (Figure S5a, 
b). Food intake and locomotor activities were unaltered (Figure S6a-c), and V
．
O2 did 
not changed in vaspin Tg mice HFHS-diet mice with ANCOVA with body weight as a 
covariate (Figure S6d). The hypertrophy of adipocytes was ameliorated and the crown-
like structures were also reduced in Tg HFHS chow mice (Figure S6e). 
   For further confirmation of the phenotype of Tg mice, the standard gene-targeting 
method was used to produce vaspin knockout mice (Figure S7a). Elevation of mRNA 
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and protein expression of vaspin in the epididymal adipose tissues and serum was 
observed in vaspin+/+ HFHS chow mice; however it was not observed in vaspin-/- mice 
(Figure S7b). Vaspin-/- HFHS diet mice demonstrated increase in body weight, fat pad, 
and liver weight (Figure 2a, 2b). The size of adipocytes and the number of crown-like 
structures increased in vaspin-/- mice (Figure 2c, Figure S6f), and deterioration of 
insulin sensitivity was observed (Figure 2d, 2e, S3c, S3d).  Serum total cholesterol and 
small dense LDL cholesterol levels were significantly increased in vaspin-/- mice 
(Figure S8a-c). Serum leptin levels increased at 25 weeks of age and, in accordance 
with the results in vapsin Tg mice, serum concentration of adiponectin was not altered 
in vaspin-/- mice, suggesting that vaspin-mediated improvement of insulin tolerance is 
not dependent on the adiponectin pathway (Figure S8d, e). Triglyceride contents 
prominently increased in vaspin-/- and vaspin+/- HFHS chow mice compared with 
vaspin+/+ mice (Figure S8f, g). The impact of gene manipulation of vaspin on the body 
and fat pad weight was rather less impressive compared with the changes in insulin 
sensitivities and triglyceride contents in the liver. We thus speculated that secreted 
vaspin from visceral adipose tissue may exert such effects directly acting on liver cells 
and further investigated to identify the vaspin-interacting molecules in the liver. 
 
Vaspin interacts with 78 kDa glucose-regulated protein (GRP78; BiP). Serpin clade 
A members consist of classical serine proteases inhibitors, such as antitrypsin 
(SERPINA1) and antichymotrypsin (SERPINA3), hormone-binding proteins (SERPINA6, 
corticosteroid-binding globulin; SERPINA7, thyroxine-binding globulin), and 
angiotensinogen (SERPINA8). The diverse function of serpin clade A members lead us 
to further screen and search for the molecules interacting with vaspin. We failed to 
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demonstrate that vaspin inhibits the activities of known serine proteases. Vaspin failed 
to bind to cortisol and thyroxine, and vaspin did not alter the protease cascades in renin 
angiotensin and complement systems. We further screened the interacting molecules by 
tandem affinity tag purification. pCTAP-Vaspin-Ad was applied to HepG2 cells, 
purified by calmodulin and streptavidin resin, subjected to SDS-PAGE, and in-gel 
digestion with trypsin, and analysed by LC-MS/MS, and we identified GRP78 as an 
interacting molecule in HepG2 cells. Since GRP78 was not isolated in the 
nontransfected cell lysates, GRP78 specifically bound to vaspin but not to calmodulin 
and streptavidin resin (Figure 3a). Immunoprecipitation study indicated the presence of 
vaspin-GRP78 complex in HepG2 cells supplemented with rhVaspin in the culture 
media, and it was not found in HepG2 cells, in which vaspin was not expressed (Figure 
3b).  Pull-down assay demonstrated the physical binding between in vitro-translated 
GRP78 and glutathione S-trasnferase (GST)-vaspin recombinant proteins (Figure 3c) as 
well as between GST-GRP78 and in vitro-translated vaspin proteins (Figure 3d). By 
pull-down assay, GST-vapsin21-249/α1AT254-417 bound to GRP78 but GST-α1AT26-
253/vapsin250-413 failed to bind GRP78,  suggesting that GRP78 bound to the NH2-
terminal half of vaspin, avoiding the reactive site loop at COOH-terminal, which is a 
conserved domain of serpin (Figure S9a). In pull-down assays, the binding between 
GST-vaspin and GRP78 was inhibited by the addition of anti-GRP78 (C-20) (Figure 
S9b) and the binding between immobilized GRP78 and vaspin in solid-phase binding 
assay was inhibited by both anti-GRP78 (N-20) and anti-GRP78 (C-20) at the 
concentration of 40 μg/ml (Figure S9c). GRP78 has NH2-terminal nucleotide-binding 
domain, a compact β-sandwich domain harbouring a cleft for substrate binding and a lid 
domain with α-helical structure at COOH-terminal end(17). Anti-GRP78 (N-20) and 
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anti-GRP78 (C-20) were raised against ATP-binding domain and COOH-terminal lid 
domain, respectively.  Thus, the binding between vaspin and GRP78 is disrupted by 
interference of the conformation of ATP-binding and COOH-terminal lid domains. We 
also demonstrated the colocalization of vaspin and GRP78 in HepG2 cells that were 
transfected with adenovirus expressing full-length of mouse vaspin (vaspin-Ad) by double 
immunostaining methods (Figure S10). 
 
Vaspin is a ligand for plasma membrane-associated GRP78. We investigated the 
expression of known GRP78-associated anchor proteins, MTJ-1, ATF6, IRE1α, and 
PERK, in the liver. We performed Western blot analysis using cell fractions of liver 
tissues of Tg and WT mice. We demonstrated the expression of MTJ-1 in the plasma 
membrane fractions of the livers from HFHS chow-fed mice (Figure S11).  The 
biotinylated cell-surface proteins in H-4-II-E-C3 cells were isolated by NeutrAvidin 
agarose resin, and Western blot analysis revealed that vaspin, GRP78, and MTJ-1 co-
existed as cell-surface proteins (Figure S11e). Furthermore, through use of the plasma 
membrane fractions of the liver, vaspin coprecipitated with GRP78 and MTJ-1 (Figure 
S11f) and GRP78 coprecipitated with MTJ-1 in both vaspin Tg and WT mice (Figure 
S11g), suggesting that they formed a complex in the plasma membrane fractions. α2M 
is a known ligand for GRP78/MTJ-1, which induces phosphorylation of Akt. In pull-
down and solid-phase binding assays, α2M did not efficiently compete with the binding 
between vaspin and GRP78 (Figure S12a, b); however, vaspin and α2M were 
colocalized in the sinusoidal front of liver cells in vaspin Tg mice (Figure S12c). Since 
α2M is abundant in serum ( ~100 mg/dL) and serum vaspin levels have been reported to 
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be ~1-10 ng/mL, the binding affinity of vaspin is quite high compared with α2M and 
excess amount of α2M is required to compete with vaspin.  
Phosphorylation of Akt was enhanced in Tg and suppressed in vaspin-/- mice treated 
with HFHS diet (Figure 4a). Similarly, phosphorylation of AMPK was markedly 
enhanced in Tg mice and suppressed in vaspin-/- mice, without alterations in the 
expression of Sirt1 or peroxisome proliferator-activated receptor g coactivator 1α 
(Figure 4a, Figure S13The addition of rhVaspin in the culture also increased the 
phosphorylation of Akt and AMPK in H-4-II-E-C3 in a dose-dependent manner (Fig. 
4B). The application of anti-GRP78 (N-20) and anti-GRP78 (C-20) completely 
abrogated the vaspin-induced phosphorylation of Akt (Figure 4c). The activation of 
pAMPK was also efficiently repressed by anti-GRP78 (N-20) and anti-GRP78 (C-20)  
(Figure 4c). Although the vaspin-binding site on GRP78 is still unknown, the data 
suggested that ATP domain at NH2-terminal and highly helicated COOH-terminal lid 
domain of GRP78 are important for the vaspin-induced intracellular signaling. Since 
GRP78 was recruited from ER to plasma membrane fractions under ER stress, we also 
investigated the ER stress–related markers in vaspin Tg and vaspin-/- mice under HFHS. 
Among ER stress–related factors, upregulation of ATF6, pelF2α and pIRE1α by HFHS 
treatments was ameliorated in vaspin Tg mice; in contrast, they were upregulated in 
vaspin-/- HFHS mice compared with vaspin+/+ mice  (Figure S13). 
To further confirm that vaspin is an authentic ligand for cell-surface GRP78 
complex, we performed the knockdown experiments in vaspin Tg mice and H-4-II-E-C3 
cells.  The expression of GRP78 was reduced by ;40% by the treatment of in vivo–
injected siRNA-GRP78 (Figure 5a). Glucose tolerance tests revealed that siRNA-
GRP78 treatment deteriorated glucose tolerance in both vaspin Tg and WT mice, and 
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the insulin-sensitizing action of overexpressed vaspin disappeared in vaspin Tg mice 
(Figure 5b and 5c). Binding assay using 125I-vaspin in isolated membrane fractions of 
the liver and H-4-II-E-C3 cells revealed high-affinity binding with Kd values, 22.2 × 
10-9 M and 0.57 × 10-9 mol/L, respectively.  The treatments of siRNA-GRP78 and 
shRNA-GRP78 lentivirus did not alter the binding affinity (24.0 × 10-9 mol/L and 0.53 
× 10-9M in liver and H4-II-E-C3 cells, respectively); however they reduced Bmax both 
in vivo and in vitro (Figure 5d and 5e). 
 
Discussion 
GRP78 is an ER chaperone which binds to hydrophobic patches of nascent 
polypeptides in ER and serves as a switch for the induction of UPR. GRP78 directly 
binds to IRE1α, ATF6 and PERK under normal condition. Under ER stress, the 
available pool of GRP78 is occupied by preventing the aggregation of unfolded proteins, 
and GRP78 releases IRE1a, ATF6, and PERK, which are transducers of the UPR 
signals (1). Beyond the ER retention, GRP78 is also associated with various anchor 
membrane proteins on the cell surface and functions as a receptor for various ligands 
and a signaling hub for cell survival or death (18–21). In many tumor cells, α2M binds 
to cell-surface GRP78/MTJ-1, activates phosphatidylinositol 3-kinase/Akt signal to 
suppress apoptotic pathways, concomitantly upregulates NFkB, and induces UPR so 
that cell proliferation occurs(22-25). In addition to α2M, teratocarcinoma-derived 
growth factor-I (Cripto) and GRP78 form a complex at the cell surface and enhance the 
cell growth by inhibiting transforming growth factor-β signalling events(26). Truncated 
cadherin and GRP78 exert the activation of Akt and promote the survival of vascular 
endothelial cells (27). In obesity associated with metabolic dysfunction, plasmalemmar 
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GRP78/MTJ-1 is induced in the liver, and the association of vaspin and GRP78/MTJ-1 
transduces the intracellular signaling such as activation of Akt and AMPK, which 
results in the improvement of both glucose and lipid metabolism. The activation of Akt 
and AMPK was demonstrated in the liver of vaspin Tg mice, the downregulation was 
observed in vaspin-/- HFHS-diet mice, and the activation of Akt and AMPK signaling 
was also confirmed in cultured H-4-II-E-C3 cells. In addition, major ER stress pathways 
such as ATF6, pelF2a, and pIRE1a were enhanced in vaspin-/- HFHS mic. Thus, vaspin 
modulates the ER stress responses through outside-in signal via cellsurface GRP78, and 
it has beneficial effects on multiple organs by ameliorating the metabolic dysfunction 
and inflammatory responses in obesity.  Energy expenditure, oxygen consumption, was 
not significantly altered in vaspin Tg or vapsin-/- mice; however, a reduction of body 
weight in vaspin Tg HFHS mice and an increase in body weight in vapsin-/- HFHS mice 
were observed. One can speculated that the methods of measuring food intake and 
energy expenditure are not sensitive enough to detect differences or that food absorption 
may be altered in vaspin Tg and in vapsin-/- mice. We demonstrated the alteration of ER 
stress molecules in the current investigation; we can speculate that vaspin may alter the 
ER stress primarily as opposed to vaspin directly regulating energy expenditure. 
Targeting GRP78 for therapeutics against obesity, autoimmune diseases, and cancers 
has been postulated (1; 18). In obesity with metabolic dysfunction, GRP78 expression 
inhibits the insulin- and ER stress-induced hepatic steatosis in db/db mice(6). Although 
GRP78 heterozygocity attenuates the diet-induced obesity and insulin resistance, Ye et 
al. (5) discuss the hypothesis that compensatory upregulation of GRP94 and protein 
disulfide isomerase, as well as other adaptive UPRs, is responsible for the therapeutic 
effects. Since the combination of GRP78 with ligands and associated anchor proteins 
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exerts diverse biological consequences such as cell survival and apoptosis, vaspin itself, 
anti-GRP78 antibodies or GRP78-interacting small molecules mimicking beneficial 
action of vaspin needs to be screened for the treatment of metabolic syndrome. In 
autoimmune diseases, anti-citrullinated protein antibodies, specific autoantibodies in 
rheumatoid arthritis, bind to GRP78 and enhance NFκB activity and tumor necrosis 
factor-α production (28). Thus, anti-GRP78 antibodies and GRP78-interacting small 
molecules should be functionally tested as to whether they have 
antiapoptotic/proapoptotic potentials or anti-inflammatory/ proinflammatory properties.  
α2M binds to cell-surface GRP78/MTJ-1, induces NFκB activity, and activates 
phosphatidylinositol 3-kinase/Akt signal, which results in antiapoptosis, cell 
proliferation, and survival of tumor cells (21). Thus, the signals downstream of vaspin-
GRP78/MTJ-1 pathways may induce NFκB activity and production of proinflammatory 
cytokines in the setting of obesity and metabolic syndrome. In the current study, 
however, vaspin ameliorated ER stress and exerted anti-inflammatory actions in liver 
via vaspin-GRP78/MTJ-1 pathway (Fig. 6). Similar findings have been reported, i.e., 
that vaspin inhibits NFκB activation and prevents tumor necrosis factor-α–induced 
expression of intracellular adhesion molecule-1 in vascular smooth muscle cells (29). 
There are some limitations to the current investigation. Since the treatment with 
siRNA-GRP78 deteriorated glucose tolerance in both vaspin Tg and WT mice in the 
current study, the GRP78-induced beneficial effects in obesity were not completely 
dependent on the vaspinmediated pathway; thus, targeting the GRP78 may be beneficial 
rather than using vaspin itself for the development of new therapeutic modalities. 
Another limitation is that direct biological actions of vaspin on adipose tissues were not 
clearly demonstrated in the study. GRP78 is also expressed in the adipocytes in vivo, 
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and vaspin is expressed in both intracellular and extracellular compartments. Vaspin 
may exert various biological effects on adipocytes such as reduction of adipocyte size 
and anti-inflammatory action by interacting with cell-surface GRP78 or ER-associated 
GRP78. Precise mechanisms of the direct action of vaspin on adipose tissues remain to 
be investigated in future studies. The last limitation is that where vaspin binds to the 
region of GRP78 is still uncharacterized. α2MG binds to the region at amino acids 98-
115(30) and competed with the binding of vaspin on GRP78. In addition, both anti-
GRP78 N-20 and C-20 antibodies interfered with the binding of GRP78, vaspin binding, 
and the subsequent signaling events. It is still not clear whether α2MG and anti-GRP78 
antibodies directly competing with vaspin or interfer the vaspin biding by the alteration 
of conformation or function of GRP78 molecules. 
Poor prognosis of the majority of tumors correlates with the expression of cell-
surface GRP78 and presence of autoantibodies, which mediates prosurvival signals and 
responses to cellular stress. Thus, blocking anti-GRP78 antibodies, small molecule 
inhibitors, anti–cancer agent conjugated with vehicle targeted to GRP78, or GRP78 
promoter–driven expression of suicide genes may be expected in the treatment of 
cancers (18). Vaspin indeed has a beneficial role in obesity in the metabolic 
dysfunctions, and the only concern to be addressed is whether vaspin promotes the 
tumor growth by acting on the cellsurface GRP78 on tumor cells. However, the lack of 
apparent carcinogenesis processes in vaspin Tg mice in our experiments negates the 
possibilities of development of neoplasm. Taken together, targeting GRP78 by vaspin or 
vaspin-mimicking antibodies or small molecules is beneficial for therapeutics for 
obesity and its related insulin resistance by ameliorating ER stress in the liver. 
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Figure legends 
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Figure 1 Phenotype of WT and vaspin Tg mice: A: Body weight of WT and vaspin 
Tg mice fed standard (STD) and HFHS chow (n = 20). B: Epididymal fat and liver 
weight of WT and vaspin Tg mice at 25 weeks of age (n = 5–9). B.W., body weight. C: 
Oil Red O staining of liver and triglyceride contents of WT and vaspin Tg mice at 25 
weeks of age. Triglyceride contents were normalized by liver weight, and fold changes 
compared with WT normal chow mice are indicated. Bar = 300 mm (n = 5–9). D: 
Glucose tolerance test at 12 weeks of age (1.5 mg/kg body wt i.p.) (n = 5–9). E: Insulin 
tolerance test at 12 weeks of age (0.75 units/kg body wt i.p. for standard chow and 1.0 
units/kg body wt i.p. for HFHS) (n = 4–10). All values are presented as means 6 SEM. 
*P < 0.05, **P < 0.01 vs. WT HFHS mice; #P < 0.05, ##P < 0.01 vs. WT HFHS mice. 
(A high-quality digital representation of this figure is available in the online issue.) 
 
Figure 2 Phenotype of vaspin+/+, vaspin+/- and vaspin-/- mice. A: Body weight of 
vaspin+/+, vaspin+/-, and vaspin-/- fed standard (STD) and HFHS chow (n = 20). B: 
Epididymal fat and liver weight of vaspin+/+, vaspin+/-, and vaspin-/-  mice at 25 weeks of 
age (n = 8–12). B.W., body weight. C: The adipocyte size of epididymal fat pad and 
histological appearance in periodic acid Schiff staining (bar = 100 mm) (n = 5). D: 
Glucose tolerance test at 12 weeks of age (1.5 mg/kg body wt i.p.). E: Insulin tolerance 
test at 12 weeks of age (0.75 units/kg body wt i.p. for standard chow and 1.0 units/kg 
body wt i.p. for HFHS) (n = 5–7). Values are presented as means 6 SEM in A–E. *P < 
0.05, **P < 0.01 vs. vaspin+/+ HFHS mice; #P < 0.05, ##P < 0.01 vs. vaspin+/+ HFHS 
mice. (A high-quality digital representation of this figure is available in the online 
issue.) 
 
Figure 3 Identification of GRP78 and vaspin complex by tandem affinity tag 
purification. A: pCTAP-vaspin-Ad was applied to HepG2, and purified products are 
analyzed by SDS-PAGE. In-gel digestion with trypsin and analysis by LC-MS/MS 
revealed that band 1 is GRP78 and band 2 is vaspin. B: HepG2 was treated with vaspin 
recombinant protein. Vaspin-GRP78 complex was immunoprecipitated by vaspin 
antibody and blotted with GRP78 antibodies. C: Pull-down assay using GST-vaspin 
fusion protein and in vitro–translated GRP78. D: Pull-down assay using GST-GRP78 
fusion 
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protein and in vitro–translated vaspin. (A high-quality color representation of this figure 
is available in the online issue.) 
 
Figure 4 Western blot analyses of liver and cultured cells. A: Western blot analyses 
of the livers from WT, vaspin Tg, vaspin+/+, vaspin+/-, and vaspin-/- mice fed standard 
(STD) and HFHS chow. Upregulation of pAkt and pAMPK was noted in vaspin Tg 
mice, and pAkt and pAMPK were downregulated in vaspin-/- HFHS mice. ATF6, 
pelF2α, and pIRE1 α were upregulated in vaspin-/- HFHS mice. B: In H-4-II-E-C3 cells, 
pAkt and pAMPKwere enhanced by treatment of rhVaspin. C: Non-target shRNA 
control lentivirus transduction particles upregulated basal activity of pAkt; 
however, treatment of shRNA lentivirus for MTJ-1 and GRP78.  
 
Figure 5 Knockdown experiments by siRNA and shRNA lentivirus for GRP78. A: 
Glucose tolerance test in WT and vaspin Tg HFHS mice and siRNAGRP78(n = 3). 
With the treatment of siRNA-GRP78, beneficial effects in glucose tolerance in vaspin 
Tg mice were not observed. B: Glucose tolerance test in WT and vaspin Tg mice fed 
HFHS chow and treated with siRNA negative control (siRNA-CTRL) (n = 3). *P < 0.05 
vs. WT HFHS mice treated with siRNA negative control. C: Western blot analyses of 
liver tissues. D: The binding activity of 125I-vaspin using liver membrane fractions in 
vaspin Tg mice fed HFHS chow. Binding affinity of 125I-vaspin was not altered by the 
treatment of siRNA-GRP78 by Scatchard analysis. Bmax was reduced in the isolated 
liver membranes by the treatment of siRNA-GRP78. *P < 0.05 vs. siRNA negative 
control. E: Cell binding assay of 125I-vaspin using cultured H-4-II-E-C3. Bmax was 
reduced in H-4-II-E-C3 cells by the treatment of shRNA-GRP78 lentivirus. *P < 0.05 vs. 
shRNA negative control. Kd, dissociation constant. 
 
Figure 6 Schematic drawing of mechanism of vaspin action in hepatocyte.  
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